Special items: Ovarian Cancer and Us blog best viewed in Firefox

Monday, February 21, 2011

Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: Final results from CAL

Note: side effects

INTERPRETATION: ZA every 3 months is well tolerated and prevents rapid bone loss in premenopausal women that develop CIOF. Giving ZA with rather than 1 year after the start of adjuvant chemotherapy is the preferred sequence to prevent bone loss.

No comments:

Post a Comment

Your comments?

Note: Only a member of this blog may post a comment.